Researchers test canine non-Hodgkin's lymphoma vaccine

10/19/2011 | ScienceDaily

Researchers from the University of Pennsylvania's schools of Medicine and Veterinary Medicine developed a vaccine for dogs with spontaneous non-Hodgkin's lymphoma that increased survival time. The vaccine uses the patient's own RNA and easy-to-isolate B-cells, as opposed to other attempts that used dendritic cells, which are cumbersome to produce. When relapse occurred after standard chemotherapy, 40% of the vaccinated dogs had long-term survival after a second round of chemotherapy, versus only 7% of non-vaccinated dogs.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Director, Site Quality Management
Minneapolis, MN